MA31433B1 - Inhibiteurs de la p70 s6 kinase - Google Patents

Inhibiteurs de la p70 s6 kinase

Info

Publication number
MA31433B1
MA31433B1 MA32404A MA32404A MA31433B1 MA 31433 B1 MA31433 B1 MA 31433B1 MA 32404 A MA32404 A MA 32404A MA 32404 A MA32404 A MA 32404A MA 31433 B1 MA31433 B1 MA 31433B1
Authority
MA
Morocco
Prior art keywords
inhibitors
inhibitors kinase
kinase
formula
methods
Prior art date
Application number
MA32404A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Robert Dean Dally
Jianping Huang
Sajan Joseph
Timothy Alan Shepherd
Christian L Holst
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA31433B1 publication Critical patent/MA31433B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA32404A 2007-05-11 2009-12-07 Inhibiteurs de la p70 s6 kinase MA31433B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91733107P 2007-05-11 2007-05-11
PCT/US2008/062143 WO2008140947A1 (en) 2007-05-11 2008-05-01 P70 s6 kinase inhibitors

Publications (1)

Publication Number Publication Date
MA31433B1 true MA31433B1 (fr) 2010-06-01

Family

ID=39765082

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32404A MA31433B1 (fr) 2007-05-11 2009-12-07 Inhibiteurs de la p70 s6 kinase

Country Status (33)

Country Link
US (2) US8093383B2 (cg-RX-API-DMAC10.html)
EP (1) EP2148880B1 (cg-RX-API-DMAC10.html)
JP (1) JP5503532B2 (cg-RX-API-DMAC10.html)
KR (1) KR101088219B1 (cg-RX-API-DMAC10.html)
CN (1) CN101679439B (cg-RX-API-DMAC10.html)
AR (1) AR066344A1 (cg-RX-API-DMAC10.html)
AU (1) AU2008251692B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0811212A2 (cg-RX-API-DMAC10.html)
CA (1) CA2687265C (cg-RX-API-DMAC10.html)
CL (1) CL2008001230A1 (cg-RX-API-DMAC10.html)
CO (1) CO6241109A2 (cg-RX-API-DMAC10.html)
CR (1) CR11106A (cg-RX-API-DMAC10.html)
DK (1) DK2148880T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2009000257A (cg-RX-API-DMAC10.html)
EA (1) EA016445B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP099721A (cg-RX-API-DMAC10.html)
ES (1) ES2483726T3 (cg-RX-API-DMAC10.html)
GT (1) GT200900292A (cg-RX-API-DMAC10.html)
HR (1) HRP20140611T1 (cg-RX-API-DMAC10.html)
IL (1) IL201564A (cg-RX-API-DMAC10.html)
MA (1) MA31433B1 (cg-RX-API-DMAC10.html)
MX (1) MX2009012075A (cg-RX-API-DMAC10.html)
MY (1) MY154898A (cg-RX-API-DMAC10.html)
NZ (1) NZ580423A (cg-RX-API-DMAC10.html)
PE (1) PE20090887A1 (cg-RX-API-DMAC10.html)
PL (1) PL2148880T3 (cg-RX-API-DMAC10.html)
PT (1) PT2148880E (cg-RX-API-DMAC10.html)
RS (1) RS53451B (cg-RX-API-DMAC10.html)
SI (1) SI2148880T1 (cg-RX-API-DMAC10.html)
TN (1) TN2009000446A1 (cg-RX-API-DMAC10.html)
TW (1) TWI423805B (cg-RX-API-DMAC10.html)
UA (1) UA99284C2 (cg-RX-API-DMAC10.html)
WO (1) WO2008140947A1 (cg-RX-API-DMAC10.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
US8252791B2 (en) * 2008-08-13 2012-08-28 Jenrin Discovery, Inc. Purine compounds as cannabinoid receptor blockers
AU2009314336B2 (en) 2008-11-11 2013-09-12 Eli Lilly And Company P70 S6 kinase inhibitor and EGFR inhibitor combination therapy
CA2743242A1 (en) * 2008-11-11 2010-05-20 Eli Lilly And Company P70 s6 kinase inhibitor and mtor inhibitor combination therapy
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
KR101699991B1 (ko) 2009-02-11 2017-01-26 메르크 파텐트 게엠베하 신규의 아미노 아자헤테로시클릭 카르복사미드
EA020302B1 (ru) 2009-08-07 2014-10-30 Мерк Патент Гмбх Новые азагетероциклические соединения
ES2465094T3 (es) 2009-10-23 2014-06-05 Eli Lilly And Company Inhibidores de AKT
JP6114554B2 (ja) 2010-02-03 2017-04-12 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤に対する感受性についての予測的なバイオマーカーとしてのｌｋｂ１変異の同定
WO2012016001A1 (en) 2010-07-29 2012-02-02 Merck Patent Gmbh Cyclic amine azaheterocyclic carboxamides
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
KR101894116B1 (ko) 2010-11-24 2018-08-31 메르크 파텐트 게엠베하 퀴나졸린 카르복사미드 아제티딘
EP2755965B1 (en) * 2011-09-12 2017-07-26 Merck Patent GmbH Novel imidazole amines as modulators of kinase activity
CN103930407B (zh) 2011-09-12 2019-02-26 默克专利有限公司 用作激酶活性调节剂的氨基嘧啶衍生物
MX2015002887A (es) * 2012-09-06 2015-07-06 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CA2890345A1 (en) * 2012-11-16 2014-05-22 Merck Patent Gmbh Imidazol-piperidinyl derivatives as modulators of kinase activity
ES2620119T3 (es) 2012-11-16 2017-06-27 Merck Patent Gmbh Derivados heterocíclicos novedosos como moduladores de la actividad de quinasa
WO2014085528A1 (en) 2012-11-29 2014-06-05 Merck Patent Gmbh Azaquinazoline carboxamide derivatives
HK1218756A1 (zh) 2013-03-11 2017-03-10 默克专利有限公司 用作激酶活性调节剂的6-[4-(1h-咪唑-2-基)哌啶-1-基]嘧啶-4-胺衍生物
SG10201708111YA (en) 2013-04-17 2017-11-29 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
TW201521725A (zh) 2013-04-17 2015-06-16 Signal Pharm Llc 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
CA2909629C (en) 2013-04-17 2022-12-13 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
MX377267B (es) 2013-04-17 2025-03-07 Signal Pharm Llc Tratamiento de cáncer con dihidropirazino-pirazinas.
TWI631949B (zh) 2013-04-17 2018-08-11 標誌製藥公司 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
CA3143529A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AU2015240094B2 (en) 2014-04-03 2020-07-30 Merck Patent Gmbh Combinations of cancer therapeutics
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2016040078A1 (en) * 2014-09-10 2016-03-17 Eli Lilly And Company Substituted phenyl imidazolyl piperidyl compounds as p70s6k1 inhibitors
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
BR112019027402A2 (pt) 2017-06-22 2020-07-07 Celgene Corporation tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b
EP4243819A1 (en) 2020-11-16 2023-09-20 Merck Patent GmbH Kinase inhibitor combinations for cancer treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
CA2563699C (en) * 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
EP1907383A1 (en) 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
EP3421471B1 (en) 2006-04-25 2021-05-26 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2007125310A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
CO6241109A2 (es) 2011-01-20
UA99284C2 (ru) 2012-08-10
TW200848053A (en) 2008-12-16
CN101679439B (zh) 2013-09-11
SI2148880T1 (sl) 2014-07-31
ECSP099721A (es) 2009-12-28
BRPI0811212A2 (pt) 2014-10-29
TWI423805B (zh) 2014-01-21
AU2008251692B2 (en) 2012-10-11
RS53451B (sr) 2014-12-31
WO2008140947A1 (en) 2008-11-20
EA016445B1 (ru) 2012-05-30
HRP20140611T1 (hr) 2014-08-15
ES2483726T3 (es) 2014-08-07
CN101679439A (zh) 2010-03-24
KR101088219B1 (ko) 2011-11-30
TN2009000446A1 (en) 2011-03-31
MX2009012075A (es) 2009-11-19
CR11106A (es) 2010-04-12
PT2148880E (pt) 2014-08-28
JP2010526814A (ja) 2010-08-05
DOP2009000257A (es) 2010-03-31
DK2148880T3 (da) 2014-06-16
AU2008251692A1 (en) 2008-11-20
EP2148880A1 (en) 2010-02-03
CA2687265C (en) 2012-12-04
HK1140767A1 (en) 2010-10-22
US20120071490A1 (en) 2012-03-22
JP5503532B2 (ja) 2014-05-28
GT200900292A (es) 2011-06-24
IL201564A0 (en) 2010-05-31
US8093383B2 (en) 2012-01-10
NZ580423A (en) 2012-02-24
AR066344A1 (es) 2009-08-12
EA200971051A1 (ru) 2010-06-30
IL201564A (en) 2014-08-31
EP2148880B1 (en) 2014-05-28
CA2687265A1 (en) 2008-11-20
CL2008001230A1 (es) 2009-05-22
PE20090887A1 (es) 2009-07-13
US20090163714A1 (en) 2009-06-25
MY154898A (en) 2015-08-28
KR20100005710A (ko) 2010-01-15
PL2148880T3 (pl) 2014-10-31

Similar Documents

Publication Publication Date Title
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
MA47301B1 (fr) Inhibiteurs sélectifs de jak1
MA32776B1 (fr) Inhibiteurs de l'akt et de la p70 s6 kinase
MA30531B1 (fr) Anticorps anti-dll4 et leurs procedes d'utilisation
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MA33492B1 (fr) Inhibiteurs de bace
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
NO20073601L (no) Immunresponsmodifikator-skumformuleringer
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
WO2009024611A3 (en) 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
MA29799B1 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MY148634A (en) Pyridazinone derivatives
EP2184984A4 (en) DERIVATIVES OF N- (ARYLAMINO) SULPHONAMIDES WITH POLYMORPHES AS MEK-INHIBITORS AND COMPOSITIONS THEREOF, METHOD FOR THEIR USE AND METHOD FOR THEIR PREPARATION
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
EA201170832A1 (ru) Пуриновые соединения
MA30042B1 (fr) Composes calcilytiques